文献速递肝病

血清白介素-6升高识别肝硬化患者显性肝性脑病高风险

Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-03

校正混杂因素后IL-6仍独立相关,预测180天内显性肝性脑病的AUROC为0.931,最佳截断值23.5 pg/mL。

要点

  • IL-6高于中位数9 pg/mL与显性肝性脑病风险独立相关。
  • IL-6预测180天内显性肝性脑病AUROC 0.931,优于MELD和CRP。
  • 无既往显性肝性脑病者,IL-6预测AUROC达0.966。

核心结论

  • 血清IL-6水平与肝硬化患者显性肝性脑病的发生密切相关。
  • IL-6高于中位数是显性肝性脑病发生的独立危险因素。

研究设计与样本

  • 前瞻性队列研究,纳入201例肝硬化患者,平均随访322天。
  • 采用West-Haven标准(肝性脑病1级)和PSE试验诊断隐匿性肝性脑病。

主要发现

  • 校正隐匿性肝性脑病、显性肝性脑病病史、CRP和MELD后,IL-6高于中位数仍独立相关。
  • 预测180天内显性肝性脑病,IL-6的AUROC为0.931,MELD为0.841,CRP为0.835。
  • 无既往显性肝性脑病者,IL-6的AUROC为0.966,显著高于MELD(0.843)和CRP(0.850)。
  • 最佳截断值23.5 pg/mL,敏感度89.3%,特异度89.5%。

临床怎么用

  • 在肝硬化患者中可检测血清IL-6,辅助识别显性肝性脑病高风险个体。
  • IL-6高于中位数9 pg/mL提示需加强显性肝性脑病监测。
  • 无既往显性肝性脑病者,IL-6预测价值更高,可优先用于早期风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic inflammation is a driving force for the development of hepatic encephalopathy and recent studies demonstrated that elevated Interleukin-6 (IL-6) serum levels are associated with the presence of minimal hepatic encephalopathy in patients with liver cirrhosis. AIM: To test the hypothesis that IL-6 is a suitable marker to identify patients with liver cirrhosis at high risk for the development of overt hepatic encephalopathy. METHODS: 201 patients were included into this prospective cohort study and were followed for a mean time of 322 days. Covert hepatic encephalopathy was diagnosed according to the West-Haven criteria (hepatic encephalopathy grade 1) and with the portosystemic encephalopathy (PSE) test. RESULTS: The cumulative incidence of overt hepatic encephalopathy was higher in patients with IL-6 levels above the median of 9 pg/mL than in patients with IL-6 levels at or below the median (35.6% vs 1.9%, P < .001). After adjustment for covert hepatic encephalopathy, history of overt hepatic encephalopathy, C-reactive protein (CRP) and model for end-stage liver disease (MELD), IL-6 levels above the median remained independently associated with the development of overt hepatic encephalopathy. The predictive performance of IL-6 regarding the development of overt hepatic encephalopathy during the next 180 days (AUROC, 0.931) was numerically higher than that of MELD (AUROC, 0.841) or CRP (AUROC, 0.835). In patients without prior overt hepatic encephalopathy, the predictive performance of IL-6 (AUROC, 0.966) was even significantly higher than that of MELD (AUROC 0.843) or CRP (AUROC 0.850). The ideal cut-off for IL-6 in this setting was 23.5 pg/mL with a sensitivity and specificity of 89.3% and 89.5% respectively. CONCLUSION: IL-6 serum levels are closely linked to the development of overt hepatic encephalopathy in patients with liver cirrhosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Labenz C, Toenges G, Huber Y, et al. Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. Aliment Pharmacol Ther. 2019. PMID: 31583743. doi:10.1111/apt.15515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。